Do analysts prefer RDY or SUPN?

Supernus Pharmaceuticals has a consensus price target of $62.83, suggesting a potential upside of 30.17%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Supernus Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media refer more to RDY or SUPN?

In the previous week, Dr. Reddy's Laboratories had 14 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 17 mentions for Dr. Reddy's Laboratories and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Dr. Reddy's Laboratories' score of -0.27 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRNX or SUPN?

In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 3 mentions for Supernus Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.54 beat Supernus Pharmaceuticals' score of 1.03 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SUPN or ALKS?

In the previous week, Alkermes had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 9 mentions for Alkermes and 3 mentions for Supernus Pharmaceuticals. Alkermes' average media sentiment score of 1.60 beat Supernus Pharmaceuticals' score of 1.03 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to LQDA or SUPN?

In the previous week, Liquidia had 50 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 53 mentions for Liquidia and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Liquidia's score of 0.53 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 14 Very Positive mention(s) 5 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLTE or SUPN?

In the previous week, Belite Bio had 18 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 21 mentions for Belite Bio and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Belite Bio's score of 0.61 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Supernus Pharmaceuticals (SUPN) Competitors

$48.27 +1.12 (+2.38%)

As of 08/14/2026 04:00 PM Eastern

Compare

SUPN vs. RDY, CRNX, ALKS, LQDA, and BLTE

Should you buy Supernus Pharmaceuticals stock or one of its competitors? Supernus Pharmaceuticals's main competitors and comparable companies include Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Alkermes (ALKS), Liquidia (LQDA), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Dr. Reddy's Laboratories had 14 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 17 mentions for Dr. Reddy's Laboratories and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Dr. Reddy's Laboratories' score of -0.27 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has a consensus price target of $62.83, suggesting a potential upside of 30.17%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Dr. Reddy's Laboratories has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.87	$456M	$0.44	27.94
Supernus Pharmaceuticals	$718.95M	3.90	-$38.55M	-$1.92	N/A

Dr. Reddy's Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Summary

Supernus Pharmaceuticals beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Supernus Pharmaceuticals' return on equity of 11.13% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Crinetics Pharmaceuticals presently has a consensus price target of $81.00, suggesting a potential downside of 4.37%. Supernus Pharmaceuticals has a consensus price target of $62.83, suggesting a potential upside of 30.17%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Crinetics Pharmaceuticals has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 3 mentions for Supernus Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.54 beat Supernus Pharmaceuticals' score of 1.03 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,166.77	-$465.32M	-$5.04	N/A
Supernus Pharmaceuticals	$718.95M	3.90	-$38.55M	-$1.92	N/A

Summary

Supernus Pharmaceuticals beats Crinetics Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Alkermes?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Alkermes has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.90	-$38.55M	-$1.92	N/A
Alkermes	$1.67B	4.94	$241.66M	$0.38	129.11

95.2% of Alkermes shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Supernus Pharmaceuticals currently has a consensus price target of $62.83, indicating a potential upside of 30.17%. Alkermes has a consensus price target of $54.56, indicating a potential upside of 11.22%. Given Supernus Pharmaceuticals' higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Alkermes has a net margin of 3.96% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Alkermes	3.96%	4.15%	2.19%

In the previous week, Alkermes had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 9 mentions for Alkermes and 3 mentions for Supernus Pharmaceuticals. Alkermes' average media sentiment score of 1.60 beat Supernus Pharmaceuticals' score of 1.03 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Supernus Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Summary

Alkermes beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Liquidia has a net margin of 30.74% compared to Supernus Pharmaceuticals' net margin of -13.23%. Liquidia's return on equity of 149.65% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Supernus Pharmaceuticals has higher revenue and earnings than Liquidia. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	42.09	-$68.92M	$1.37	54.34
Supernus Pharmaceuticals	$718.95M	3.90	-$38.55M	-$1.92	N/A

In the previous week, Liquidia had 50 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 53 mentions for Liquidia and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Liquidia's score of 0.53 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	14 Very Positive mention(s)	5 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Liquidia currently has a consensus target price of $98.08, suggesting a potential upside of 31.76%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 30.17%. Given Liquidia's higher possible upside, equities research analysts plainly believe Liquidia is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Liquidia beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Belite Bio has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-12.63%	-12.40%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Belite Bio currently has a consensus price target of $205.80, suggesting a potential upside of 26.41%. Supernus Pharmaceuticals has a consensus price target of $62.83, suggesting a potential upside of 30.17%. Given Supernus Pharmaceuticals' higher probable upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Belite Bio had 18 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 21 mentions for Belite Bio and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Belite Bio's score of 0.61 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Supernus Pharmaceuticals	$718.95M	3.90	-$38.55M	-$1.92	N/A

Belite Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Supernus Pharmaceuticals beats Belite Bio on 9 of the 15 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SUPN vs. The Competition

Export

Metric	Supernus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.81B	$11.80B	$7.03B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.65%
P/E Ratio	-25.14	779.99	271.26	25.37
Price / Sales	3.90	748.85	622.96	106.04
Price / Cash	12.79	89.04	75.70	53.27
Price / Book	2.72	11.60	12.92	6.21
Net Income	-$38.55M	$2.77B	$3.45B	$347.71M
7 Day Performance	1.32%	0.14%	1.16%	1.08%
1 Month Performance	1.13%	0.06%	1.37%	0.82%
1 Year Performance	13.07%	145.15%	62.53%	20.99%

Supernus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SUPN Supernus Pharmaceuticals	4.1721 of 5 stars	$48.27 +2.4%	$62.83 +30.2%	+14.5%	$2.81B	$718.95M	N/A	580	Positive News
RDY Dr. Reddy's Laboratories	2.037 of 5 stars	$12.45 +2.4%	N/A	-13.0%	$10.39B	$3.58B	28.28	27,527	Analyst Revision Gap Up
CRNX Crinetics Pharmaceuticals	1.977 of 5 stars	$84.27 +0.1%	$81.00 -3.9%	+185.3%	$8.94B	$7.70M	N/A	210	Positive News
ALKS Alkermes	3.1665 of 5 stars	$49.15 -0.5%	$54.56 +11.0%	+73.6%	$8.24B	$1.48B	129.23	2,050	Positive News
LQDA Liquidia	4.5679 of 5 stars	$90.47 -0.6%	$86.18 -4.7%	+185.3%	$8.03B	$158.32M	645.02	50	Trending News Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. RDY, CRNX, ALKS, LQDA, and BLTE

How does Supernus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does Supernus Pharmaceuticals compare to Alkermes?

Summary

How does Supernus Pharmaceuticals compare to Liquidia?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. RDY, CRNX, ALKS, LQDA, and BLTE

How does Supernus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Does the media refer more to RDY or SUPN?

Do analysts prefer RDY or SUPN?

Which has better valuation & earnings, RDY or SUPN?

Which has more volatility and risk, RDY or SUPN?

Do institutionals and insiders hold more shares of RDY or SUPN?

Is RDY or SUPN more profitable?

Summary

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Do insiders and institutionals hold more shares of CRNX or SUPN?

Is CRNX or SUPN more profitable?

Do analysts rate CRNX or SUPN?

Which has more risk and volatility, CRNX or SUPN?

Does the media prefer CRNX or SUPN?

Which has preferable valuation & earnings, CRNX or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Alkermes?

Which has better valuation and earnings, SUPN or ALKS?

Do insiders & institutionals have more ownership in SUPN or ALKS?

Do analysts prefer SUPN or ALKS?

Is SUPN or ALKS more profitable?

Does the media favor SUPN or ALKS?

Which has more risk and volatility, SUPN or ALKS?

Summary

How does Supernus Pharmaceuticals compare to Liquidia?

Do insiders and institutionals hold more shares of LQDA or SUPN?

Is LQDA or SUPN more profitable?

Which has preferable earnings and valuation, LQDA or SUPN?

Does the media refer more to LQDA or SUPN?

Which has more volatility & risk, LQDA or SUPN?

Do analysts recommend LQDA or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Is BLTE or SUPN more profitable?

Do analysts prefer BLTE or SUPN?

Does the media prefer BLTE or SUPN?

Which has better earnings and valuation, BLTE or SUPN?

Which has more risk & volatility, BLTE or SUPN?

Do institutionals & insiders hold more shares of BLTE or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools